Adrienne MacMillan, Chief Financial Officer and Founder
Ivan Diamond, MD, PhD, Chief Scientific Officer and Founder
AMYGDALA PRESS RELEASE: Feb 16, 2017
Brent Blackburn, PhD, Chief Executive Officer and Founder
The Amygdala founders have deep and varied expertise in drug development and the addiction space. In addition to our individual experiences, we are all former members of the executive management team that built CV Therapeutics into a FIPCO and developed two first-in-class NCEs approved in the US and EU and achieved guideline status in both territories with current global revenues over $1.6B.
In addition to the BOD members listed above, the BOD also includes:
Lou Lange, MD, PhD, Executive Chairman and Founder
NIH PRESS RELEASE: March 21, 2019
The Board of Directors
Mack Mitchell, MD, Medical Advisor
Type your paragraph here.
MISSION: Address the Growing Unmet Need
Associated with Substance Use Disorder
By Discovering, Developing and Commercializing
Safe and Effective Pharmacotherapies
to Treat and Prevent Addiction
Based on a mechanism of action in the brain to prevent pathophysiologic dopamine surge without changes to basal dopamine (Nature Medicine 16:1024, 2010), Amygdala's ALDH2 inhibitor technology has the potential to prevent drug seeking behavior, craving and relapse. In preclinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anti-anxiety properties in models of stress.
NIH/IHV PRESS RELEASE: Sept 19, 2018
William Lee, PhD, Former Executive Vice President Research, Gilead Sciences
Howard Jaffe, MD, Former CMO Gilead Sciences
Peter Strumph, CEO, Parvus Therapeutics. Former: SVP, Portola; CEO, Codexis